OncoSil Medical Ltd is a publicly traded medical technology company (ASX: OSL) headquartered in Sydney, Australia and with a global footprint.
It has taken many committed individuals 15 years of dedication to get us to where we are today.
OncoSil™ system receives regulatory approval from Malaysia’s Medical Device Authority
OncoSil™ System receives regulatory approval from Singapore’s Health Sciences Agency
British Standards Institute (BSI) grants European CE marking for the OncoSil™ System and designates OncoSil™ a breakthrough device for the treatment of locally advanced pancreatic cancer in combination with chemotherapy
FDA grants Breakthrough Device Designation for the OncoSil™ device for treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy
The number of OncoSil™ device implantations for the PanCO study was achieved which resulted in end of study recruitment
First US study participant implanted with the OncoSil™ device as part of the OncoPaC-1 study
First study participant patient implanted with the OncoSil™ device as part of the global PanCO study
OncoSil Medical receives investigational device exemption (IDE) approval from the FDA to conduct a clinical study
Enigma Therapeutics Ltd is acquired by Neurodiscovery Ltd
Neurodiscovery Ltd changes its name to OncoSil Medical Ltd and focuses on the development of OncoSil™
pSivida Corp grants an exclusive worldwide royalty-bearing license agreement with Enigma Therapeutics Ltd for the development of BrachySil™
2004 to 2009
Early clinical development phases for the OncoSil™ technology
The OncoSil™ technology is developed as BrachySil™ by pSivida Corp